{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:30:18Z","timestamp":1790980218636,"version":"4.1.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1097\/cad.0b013e328328d18b","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T06:07:04Z","timestamp":1242886024000},"page":"259-266","source":"Crossref","is-referenced-by-count":18,"title":["Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001"],"prefix":"10.1097","volume":"20","author":[{"given":"Philipp","family":"Baumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilke","family":"Hagemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Mandl-Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Schmidmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210203","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1200\/JCO.1992.10.2.334","article-title":"Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials","volume":"10","author":"Gregory","year":"1992","journal-title":"J Clin Oncol"},{"key":"R2-5-20210203","first-page":"3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"key":"R3-5-20210203","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"R4-5-20210203","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplants for newly diagnosed multiple myeloma","volume":"93","author":"Barlogie","year":"1999","journal-title":"Blood"},{"key":"R5-5-20210203","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"R6-5-20210203","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","article-title":"Intermediate-dose melphalan improves survival of myeloma patients aged 50\u201370: results of a randomized controlled trial","volume":"104","author":"Palumbo","year":"2004","journal-title":"Blood"},{"key":"R7-5-20210203","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"R8-5-20210203","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood-2003-12-4218","article-title":"The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase","volume":"104","author":"Schmidmaier","year":"2004","journal-title":"Blood"},{"key":"R9-5-20210203","first-page":"218","article-title":"Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo","volume":"21","author":"Schmidmaier","year":"2006","journal-title":"Int J Biol Markers"},{"key":"R10-5-20210203","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.leukres.2007.11.015","article-title":"Alkylating agents induce activation of NFkappaB in multiple myeloma cells","volume":"32","author":"Baumann","year":"2008","journal-title":"Leuk Res"},{"key":"R11-5-20210203","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.yexcr.2007.06.020","article-title":"Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells","volume":"313","author":"Baumann","year":"2007","journal-title":"Exp Cell Res"},{"key":"R12-5-20210203","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood.V96.8.2856","article-title":"Insulin-like growth factor I is a dual effector of multiple myeloma cell growth","volume":"96","author":"Ge","year":"2000","journal-title":"Blood"},{"key":"R13-5-20210203","first-page":"6763","article-title":"The phosphatidylinositol 3-kinase\/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses","volume":"60","author":"Tu","year":"2000","journal-title":"Cancer Res"},{"key":"R14-5-20210203","doi-asserted-by":"crossref","first-page":"23435","DOI":"10.1016\/S0021-9258(19)49481-7","article-title":"Structure\u2013function relationship of the insulin-like growth factor-I receptor tyrosine kinase","volume":"268","author":"Gr\u00f8nborg","year":"1993","journal-title":"J Biol Chem"},{"key":"R15-5-20210203","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0006-2952(00)00422-6","article-title":"Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy","volume":"60","author":"Brodt","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"R16-5-20210203","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2174\/138161207780249146","article-title":"The IGF-I signaling pathway","volume":"13","author":"Laviola","year":"2007","journal-title":"Curr Pharm Des"},{"key":"R17-5-20210203","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1535-6108(04)00051-0","article-title":"In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase","volume":"5","author":"Garc\u00eda-Echeverr\u00eda","year":"2004","journal-title":"Cancer Cell"},{"key":"R18-5-20210203","first-page":"205","article-title":"Targeting PI3K-AKT pathway for cancer therapy","volume":"7","author":"Lu","year":"2003","journal-title":"Rev Clin Exp Hematol"},{"key":"R19-5-20210203","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1158\/0008-5472.CAN-06-0743","article-title":"Akt signaling and cancer: surviving but not moving on","volume":"66","author":"Toker","year":"2006","journal-title":"Cancer Res"},{"key":"R20-5-20210203","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1161\/01.RES.0000022200.71892.9F","article-title":"Role of Akt signaling in vascular homeostasis and angiogenesis","volume":"90","author":"Shiojima","year":"2002","journal-title":"Circ Res"},{"key":"R21-5-20210203","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1582-4934.2005.tb00337.x","article-title":"The activation of Akt\/PKB signaling pathway and cell survival","volume":"9","author":"Song","year":"2005","journal-title":"J Cell Mol Med"},{"key":"R22-5-20210203","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-2141.2008.07049.x","article-title":"The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells","volume":"141","author":"Maiso","year":"2008","journal-title":"Br J Haematol"},{"key":"R23-5-20210203","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/BF02983377","article-title":"Survival and proliferation factors of normal and malignant plasma cells","volume":"78","author":"Klein","year":"2003","journal-title":"Int J Hematol"},{"key":"R24-5-20210203","first-page":"706","article-title":"CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity","volume":"90","author":"Bataille","year":"2005","journal-title":"Haematologica"},{"key":"R25-5-20210203","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1182\/blood-2002-05-1406","article-title":"Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor","volume":"100","author":"Standal","year":"2002","journal-title":"Blood"},{"key":"R26-5-20210203","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2003-06-2066","article-title":"Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells","volume":"103","author":"Qiang","year":"2004","journal-title":"Blood"},{"key":"R27-5-20210203","first-page":"5850","article-title":"Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3\u2032-kinase\/AKT signaling","volume":"63","author":"Tai","year":"2003","journal-title":"Cancer Res"},{"key":"R28-5-20210203","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood.V85.4.997.bloodjournal854997","article-title":"Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6\/E7 genes","volume":"85","author":"Roecklein","year":"1995","journal-title":"Blood"},{"key":"R29-5-20210203","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1038\/sj.leu.2403968","article-title":"Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells","volume":"19","author":"Xu","year":"2005","journal-title":"Leukemia"},{"key":"R30-5-20210203","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.leukres.2006.08.001","article-title":"Longitudinal inhibition of PI3K\/Akt\/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells","volume":"31","author":"Ikezoe","year":"2007","journal-title":"Leuk Res"},{"key":"R31-5-20210203","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/363170a0","article-title":"P70S6k function is essential for G1 progression","volume":"363","author":"Lane","year":"1993","journal-title":"Nature"},{"key":"R32-5-20210203","doi-asserted-by":"crossref","first-page":"9666","DOI":"10.1073\/pnas.171301998","article-title":"P70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD","volume":"98","author":"Harada","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R33-5-20210203","first-page":"886","article-title":"Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells","volume":"59","author":"Hosoi","year":"1999","journal-title":"Cancer Res"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e328328d18b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:48:31Z","timestamp":1786038511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-200904000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e328328d18b","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}